Tango Therapeutics reported no revenue for the fourth quarter of 2025 as collaboration revenue ended following the Gilead agreement truncation. The company recorded a net loss of 38749000 while continuing to invest in research and development programs including vopimetostat and other oncology pipeline candidates.

Tango Therapeutics posted a net loss of $39.9 million for Q1 2025 with revenues slightly down year-over-year. The company reduced R&D spend on discontinued programs, helping extend its cash runway to Q1 2027, and continues to advance its lead PRMT5 programs.